CytomX Therapeutics Inc. (CTMX)
| Bid | 0.73 |
| Market Cap | 59.79M |
| Revenue (ttm) | 138.1M |
| Net Income (ttm) | 31.87M |
| EPS (ttm) | 0.38 |
| PE Ratio (ttm) | 1.96 |
| Forward PE | -1.55 |
| Analyst | Buy |
| Ask | 0.75 |
| Volume | 1,018,713 |
| Avg. Volume (20D) | 1,834,549 |
| Open | 0.75 |
| Previous Close | 0.75 |
| Day's Range | 0.73 - 0.78 |
| 52-Week Range | 0.40 - 5.85 |
| Beta | 1.33 |
About CTMX
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatme...
Analyst Forecast
According to 5 analyst ratings, the average rating for CTMX stock is "Buy." The 12-month stock price forecast is $5.79, which is an increase of 675.72% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago · seekingalpha.com
CytomX Therapeutics, Inc. (CTMX) Q4 2024 Earnings Call TranscriptCytomX Therapeutics, Inc. (NASDAQ:CTMX ) Q4 2024 Results Conference Call March 6, 2025 5:00 PM ET Company Participants Chris Ogden - CFO Sean McCarthy - Chairman and CEO Conference Call Participants R...
